Multaq and Hyperbilirubinaemia aggravated - a phase IV clinical study of FDA data

Summary:

Hyperbilirubinaemia aggravated is reported as a side effect among people who take Multaq (dronedarone hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Melatonin, and have Short-bowel syndrome.

The phase IV clinical study analyzes which people have Hyperbilirubinaemia aggravated when taking Multaq. It is created by eHealthMe based on reports of 10,572 people who have side effects when taking Multaq from the FDA, and is updated regularly.

What is Multaq?

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 11,053 Multaq users. Check the latest studies of Multaq.

What is Hyperbilirubinaemia aggravated?

Hyperbilirubinaemia aggravated (excess of bilirubin in the blood) is found to be associated with 811 drugs and 378 conditions by eHealthMe. Check the latest studies of Hyperbilirubinaemia aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 27, 2026

10,572 people reported to have side effects when taking Multaq.
Among them, 11 people (0.1%) have Hyperbilirubinaemia aggravated.

Could Multaq cause Hyperbilirubinaemia aggravated?

Among these 11 people:

How long have people been on Multaq when they have Hyperbilirubinaemia aggravated? *

  • < 1 month: 28.57 %
  • 1 - 6 months: 28.57 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 42.86 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Hyperbilirubinaemia aggravated when taking Multaq? *

  • female: 55.56 %
  • male: 44.44 %

What is the age of people who have Hyperbilirubinaemia aggravated when taking Multaq? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 12.5 %
  • 60+: 87.5 %

What are other drugs people take besides Multaq? *

  1. Aldara: 3 people, 27.27%
  2. Creon: 3 people, 27.27%
  3. Voriconazole: 3 people, 27.27%
  4. Glutamine: 3 people, 27.27%
  5. Famotidine: 3 people, 27.27%
  6. Imodium A-D: 3 people, 27.27%
  7. Eliquis: 3 people, 27.27%
  8. Lactobacillus Acidophilus: 3 people, 27.27%
  9. Efudex: 3 people, 27.27%
  10. Melatonin: 3 people, 27.27%

What are other side effects people have besides Hyperbilirubinaemia aggravated? *

  1. Transaminases Increased: 7 people, 63.64%
  2. Fatigue (feeling of tiredness): 3 people, 27.27%
  3. Hypertriglyceridaemia (excess of triglycerides in the blood): 3 people, 27.27%
  4. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 3 people, 27.27%
  5. Hypocalcaemia (levels of calcium in blood serum are abnormally low): 3 people, 27.27%
  6. Hypoglycemia (low blood sugar): 3 people, 27.27%
  7. Hypokalemia (low potassium): 3 people, 27.27%
  8. Urinary Tract Infection: 3 people, 27.27%
  9. Anaemia (lack of blood): 3 people, 27.27%
  10. Pleural Effusion (water on the lungs): 3 people, 27.27%

What are the existing conditions these people have? *

  1. Hypovolaemia (a decreased volume of circulating blood in the body): 3 people, 27.27%
  2. Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking): 3 people, 27.27%
  3. Diarrhea: 3 people, 27.27%
  4. Electrolyte Imbalance: 3 people, 27.27%
  5. Endophthalmitis (inflammation of the internal coats of the eye): 3 people, 27.27%
  6. Hypotension (abnormally low blood pressure): 3 people, 27.27%
  7. Hypovitaminosis (any of several diseases caused by deficiency of one or more vitamins): 3 people, 27.27%
  8. Actinic Keratosis (skin disease due to sun exposure): 3 people, 27.27%
  9. Mineral Deficiency (lack of mineral): 3 people, 27.27%
  10. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 3 people, 27.27%

* Approximation only. Some reports may have incomplete information.

Do you take Multaq and have Hyperbilirubinaemia aggravated?

- Check whether Hyperbilirubinaemia aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Multaq:

Hyperbilirubinaemia aggravated treatments and more:

How severe was Hyperbilirubinaemia aggravated and when was it recovered:

Expand to all the drugs that have ingredients of dronedarone hydrochloride:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Multaq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperbilirubinaemia aggravated:

Browse all the conditions that are associated with Hyperbilirubinaemia aggravated:


How the study uses the data?

The study uses data from the FDA. It is based on dronedarone hydrochloride (the active ingredients of Multaq) and Multaq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: